反对PD-L1表达细胞的RevCAR介导的T细胞反应将抑制转化为激活
Eugenia Crespo1, Liliana R Loureiro1, Antonia Stammberger2
1Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
NPJ precision oncology
|February 9, 2025
概括
这项研究引入了一种用于CAR T细胞治疗的新型PD-L1向系统,通过克服免疫抑制性瘤微环境 (TME) 来提高其对固体瘤的有效性. RevCAR系统在重定向T细胞以消除PD-L1表达癌细胞方面表现有前途.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 由于免疫抑制性瘤微环境 (TME),CAR T细胞疗法在固体瘤中面临挑战.
- 模块化的RevCAR系统提高了CAR T细胞治疗的安全性和控制性,但在固体瘤向方面存在困难.
- PD-L1 是一个关键的免疫检查点,在固体瘤中被上调,使其成为一个相关的治疗标.
研究的目的:
- 为RevCAR系统开发一种新的PD-L1向模块 (RevTM),以提高CAR T细胞治疗在固体瘤中的疗效.
- 评估PD-L1 RevTM重定向RevCAR T细胞以准和消除PD-L1表达瘤细胞的能力.
- 调查双RevCAR系统对表达PD-L1和另一种瘤相关抗原的瘤的AND-gated向潜力.
主要方法:
- 开发一种用于CAR T细胞重定向的新型PD-L1 RevTM.
- 使用单层和3D瘤模型进行体外试验,包括患者衍生培养.
- 在体内研究以评估治疗疗效和向.
- 对 AND-gated 定位的双 RevCAR 系统的评估.
主要成果:
- 在体外和体内,PD-L1 RevTM成功地将RevCAR T细胞重定向到专门准并杀死PD-L1表达瘤细胞.
- 激活的T细胞在准PD-L1表达细胞时分泌出促炎性细胞因子.
- 双RevCAR系统在体外和体内证明了AND-gated对共同表达PD-L1和另一种瘤抗原的细胞的向.
结论:
- 通过RevCAR介导的PD-L1向是调节固体瘤中免疫抑制TME的有希望的策略.
- 这种方法有可能提高CAR T细胞治疗各种固体恶性瘤的疗效.
- 双RevCAR系统为针对多个抗原的瘤提供了增强的特异性.
相关概念视频
Abnormal Proliferation
4.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
T Cell Activation and Clonal Selection
13.7K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
13.7K
T Cell Types and Functions
3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
Cytotoxic T Cells-mediated Immune Response
7.0K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.0K
B Cell Activation and Differentiation
14.4K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
14.4K
Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K


